Skip to main content
Funded Studies

Roger Olsson, PhD

Director of Medicinal Chemistry at Acadia Pharmaceuticals

Adjunct Professor in Medicinal Chemistry at University of Gothenburg, Sweden

Roger Olsson has been involved in a number of preclinical projects targeting central nervous system and pain/inflammation indications. Dr. Olsson’s responsibilities cover core discovery chemistry including medicinal chemistry, high-throughput medicinal chemistry and analytical chemistry. In addition, he is the program manager of a late phase preclinical discovery project.

Prior to joining ACADIA in 1999 Dr. Olsson worked at Astra, focusing on inflammation. He received a Master of Science in Chemical engineering from the University of Lund Institute of Technology and a PhD in organic chemistry from the University of Lund.


Associated Grants

  • Development of Nurr1-RXR Heterodimer Selective Agonists for Parkinson's Disease

    2012


  • Development of Nurr1-RXR Heterodimer Selective Agonists for Parkinson's Disease

    2012


  • Development of Nurr1-RXR Heterodimer Selective Agonists for Parkinson's Disease

    2010


  • Development of ERb agonists for the treatment of Parkinson's Disease

    2008


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.